SOPHiA GENETICS SA Ordinary Shares

SOPHiA GENETICS SA Ordinary Shares Earnings Recaps

SOPH Health Care 1 recap
Q3 2025 Nov 4, 2025

SOPHiA GENETICS delivered a strong Q3 2025 performance with 23% year-over-year revenue growth, driven by record new customer signings and sustained momentum in the U.S. market, prompting the company to raise its revenue guidance for the year.

Key takeaways
  • New customer signings reached 31 in Q3, bringing the total for 2025 to 94, surpassing last year’s total.
  • U.S. revenue grew 30% year-over-year as new strategic partnerships with major health systems were established.
  • The launch and global adoption of the liquid biopsy application MSK-ACCESS has seen more than 60 customers signed, with significant backing from AstraZeneca for its deployment.
  • SOPHiA's innovative Digital Twins technology aims to enhance treatment decision-making by leveraging multimodal data for oncology.
  • Full-year revenue guidance is now set between $75 million and $77 million, reflecting strong business momentum.
Full recap